Description

• General description: A Certified Spiking Solution® of an immunosuppressant and narrow therapeutic index drug used to prevent rejection in organ transplantation. This certified calibration material is suitable for critical quantitative applications in clinical and diagnostic testing such as therapeutic drug monitoring assays to ensure patients remain within the drug′s narrow therapeutic range.  The Snap-N-Spike® format allows laboratories to eliminate weighing operations of hazardous substances such as cyclosporin A, significantly reducing occupational exposure hazards related to handling of acutely toxic powders, and provides the ability to spike into their matrix of choice just before use.
• Application: Novel IgE crosslinking-induced luciferase expression method using human-rat chimeric IgE receptor-carrying mast cells: This study leverages Cyclosporin A′s immunosuppressive properties to explore new methodologies for investigating allergic responses. By utilizing Cyclosporin A to modulate immune cell activity, researchers have developed an innovative in vitro assay that significantly enhances our understanding of immune mechanisms, demonstrating Cyclosporin A′s pivotal role in immunological research and its application in developing more effective allergy treatments (Akiyama H et al., 2024).Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics: This review discusses the critical role of Cyclosporin A in the development of nanocarrier systems for targeted drug delivery, particularly for ocular applications. Cyclosporin A′s effectiveness in preventing transplant rejection and its properties as a calcineurin inhibitor make it an excellent candidate for incorporation into advanced drug delivery systems, enhancing therapeutic efficacy and reducing systemic side effects (Datta D et al., 2024).A sterilizable platform based on crosslinked xanthan gum for controlled-release of polymeric micelles: Demonstrating Cyclosporin A′s utility in enhancing the efficacy of controlled-release drug systems, this study details the use of Cyclosporin A with a novel xanthan gum-based platform. This research emphasizes Cyclosporin A′s role in the pharmaceutical industry, particularly in improving drug delivery mechanisms that can be crucial for treating chronic conditions (Signorini S et al., 2024).
• Legal Information: CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany